A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.
Kearns JD, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, Koepke S, Cochin de Billy B, Ledieu D, Andre C, Hawtin S, Fischer B, Moretti F, Hug C, Bepperling A, Brannetti B, Mendez-Garcia C, Littlewood-Evans A, Clemens A, Grosskreutz CL, Mehan P, Schmouder RL, Sasseville V, Brees D, Karle AC.
Kearns JD, et al. Among authors: brees d.
Sci Transl Med. 2023 Feb;15(681):eabq5068. doi: 10.1126/scitranslmed.abq5068. Epub 2023 Feb 1.
Sci Transl Med. 2023.
PMID: 36724241